miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma
Abstract Background Tongue squamous cell carcinoma (TSCC) is the most common oral cancer. Neoadjuvant systemic treatment before or after surgery for advanced TSCC is considered one of the most crucial factors in reducing mortality. However, the therapeutic benefits of chemotherapy are usually attenu...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-018-0834-z |
id |
doaj-46d18ca5969a45c785189a4583bb6aa7 |
---|---|
record_format |
Article |
spelling |
doaj-46d18ca5969a45c785189a4583bb6aa72020-11-25T01:44:33ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662018-07-0137111410.1186/s13046-018-0834-zmiR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinomaYixue Gu0Hao Liu1Fangren Kong2Jiahui Ye3Xiaoting Jia4Zhijie Zhang5Nan Li6Jiang Yin7Guopei Zheng8Zhimin He9Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAffiliated Cancer Hospital & Institute of Guangzhou Medical UniversityAbstract Background Tongue squamous cell carcinoma (TSCC) is the most common oral cancer. Neoadjuvant systemic treatment before or after surgery for advanced TSCC is considered one of the most crucial factors in reducing mortality. However, the therapeutic benefits of chemotherapy are usually attenuated due to intrinsic and/or acquired drug resistance, and a large proportion of TSCC are resistant to chemotherapy, which may result in more aggressive tumor behavior and an even worse clinical outcome. Recently, the potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise, but miRNAs with predictive value remain to be identified and underlying mechanisms remain to be understood in TSCC. Methods The expression of miR-22 in tissues from patients diagnosed with TSCC was analyzed using real-time PCR. The effects of miR-22 on cell proliferation and tumorigenesis in TSCC cells were analyzed by MTS assay, and flow cytometry. The tumor growth in vivo was observed in xenograft model. Luciferase reporter assay, real-time PCR and western blot were performed to validate a potential target of miR-22 in TC. The correlation between miR-22 expression and KAT6B expression, as well as the mechanisms by which miR-22 regulates PI3k-Akt-NF-kB pathway in TSCC were also addressed. Results We found a strong correlation between miR-22 expression and chemosensitivity to cisplatin (CDDP) in TSCC patients. Ectopic overexpression of miR-22 enhanced TSCC cells apoptosis in response to CDDP in experimental models performed in vitro and in vivo. Moreover, we found that KAT6B is a direct functional target of miR-22. Ectopic expression of KAT6B attenuated the efficiency of miR-22 in TSCC cells upon CDDP treatment. Mechanistically, miR-22 overexpression or KAT6B knockdown inhibited PI3K/Akt/NF-κB signaling in TSCC cells, possibly via downregulating the activators of PI3K/Akt/NF-κB signaling, such as S100A8, PDGF and VEGF. Furthermore, the activation of miR-22 depended on the intensity of the stresses in the presence of p53 activation. Conclusions Our findings define miR-22 as an intrinsic molecular switch that determines p53-dependent cellular fate through KAT6B/ PI3K-Akt/ NF-kB pathway.http://link.springer.com/article/10.1186/s13046-018-0834-zTongue cancermiR-22KAT6BNF-κBp53Chemotherapy response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yixue Gu Hao Liu Fangren Kong Jiahui Ye Xiaoting Jia Zhijie Zhang Nan Li Jiang Yin Guopei Zheng Zhimin He |
spellingShingle |
Yixue Gu Hao Liu Fangren Kong Jiahui Ye Xiaoting Jia Zhijie Zhang Nan Li Jiang Yin Guopei Zheng Zhimin He miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma Journal of Experimental & Clinical Cancer Research Tongue cancer miR-22 KAT6B NF-κB p53 Chemotherapy response |
author_facet |
Yixue Gu Hao Liu Fangren Kong Jiahui Ye Xiaoting Jia Zhijie Zhang Nan Li Jiang Yin Guopei Zheng Zhimin He |
author_sort |
Yixue Gu |
title |
miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma |
title_short |
miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma |
title_full |
miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma |
title_fullStr |
miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma |
title_full_unstemmed |
miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma |
title_sort |
mir-22/kat6b axis is a chemotherapeutic determiner via regulation of pi3k-akt-nf-kb pathway in tongue squamous cell carcinoma |
publisher |
BMC |
series |
Journal of Experimental & Clinical Cancer Research |
issn |
1756-9966 |
publishDate |
2018-07-01 |
description |
Abstract Background Tongue squamous cell carcinoma (TSCC) is the most common oral cancer. Neoadjuvant systemic treatment before or after surgery for advanced TSCC is considered one of the most crucial factors in reducing mortality. However, the therapeutic benefits of chemotherapy are usually attenuated due to intrinsic and/or acquired drug resistance, and a large proportion of TSCC are resistant to chemotherapy, which may result in more aggressive tumor behavior and an even worse clinical outcome. Recently, the potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise, but miRNAs with predictive value remain to be identified and underlying mechanisms remain to be understood in TSCC. Methods The expression of miR-22 in tissues from patients diagnosed with TSCC was analyzed using real-time PCR. The effects of miR-22 on cell proliferation and tumorigenesis in TSCC cells were analyzed by MTS assay, and flow cytometry. The tumor growth in vivo was observed in xenograft model. Luciferase reporter assay, real-time PCR and western blot were performed to validate a potential target of miR-22 in TC. The correlation between miR-22 expression and KAT6B expression, as well as the mechanisms by which miR-22 regulates PI3k-Akt-NF-kB pathway in TSCC were also addressed. Results We found a strong correlation between miR-22 expression and chemosensitivity to cisplatin (CDDP) in TSCC patients. Ectopic overexpression of miR-22 enhanced TSCC cells apoptosis in response to CDDP in experimental models performed in vitro and in vivo. Moreover, we found that KAT6B is a direct functional target of miR-22. Ectopic expression of KAT6B attenuated the efficiency of miR-22 in TSCC cells upon CDDP treatment. Mechanistically, miR-22 overexpression or KAT6B knockdown inhibited PI3K/Akt/NF-κB signaling in TSCC cells, possibly via downregulating the activators of PI3K/Akt/NF-κB signaling, such as S100A8, PDGF and VEGF. Furthermore, the activation of miR-22 depended on the intensity of the stresses in the presence of p53 activation. Conclusions Our findings define miR-22 as an intrinsic molecular switch that determines p53-dependent cellular fate through KAT6B/ PI3K-Akt/ NF-kB pathway. |
topic |
Tongue cancer miR-22 KAT6B NF-κB p53 Chemotherapy response |
url |
http://link.springer.com/article/10.1186/s13046-018-0834-z |
work_keys_str_mv |
AT yixuegu mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT haoliu mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT fangrenkong mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT jiahuiye mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT xiaotingjia mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT zhijiezhang mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT nanli mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT jiangyin mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT guopeizheng mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma AT zhiminhe mir22kat6baxisisachemotherapeuticdeterminerviaregulationofpi3kaktnfkbpathwayintonguesquamouscellcarcinoma |
_version_ |
1725027955820724224 |